🇺🇸 FDA
Patent

US 10934332

Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment

granted A61KA61K38/00A61K38/08

Quick answer

US patent 10934332 (Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment) held by The Regents of the University of California expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K38/00, A61K38/08, A61K38/10, A61K38/16